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For more than a decade, a large number of patients with chronic
hepatitis B (CHB) have been treated with lamivudine or adefovir
worldwide. While these anti-viral agents have contributed signif-
icantly towards the reduction of CHB, resistance to lamivudine
and to a lesser degree to adefovir has emerged as a major barrier
in the control of viral replication. The recently published 2009
EASL Clinical Practice Guideline: ‘‘Management of Chronic Hepa-
titis B” recommends treating naïve CHB patients that are not can-
didates for interferon therapy with ‘‘the most potent drugs with
the optimal resistance proﬁle, i.e. tenofovir or entecavir as ﬁrst-
line monotherapies”. These nucleos(t)ide analogues (NA) are also
used in treating patients who developed resistance to lamivudine
or adefovir usually in an ‘‘add on” strategy. Changing treatment
from one monotherapy with an anti-viral agent to another may
lead to the emergence of new resistance patterns as shown in
patients with lamivudine resistant mutations who were switched
to entecavir. In this issue of the Journal, Reijnders and co-workers
report the results of a European multi-center study in which two
groups of patients were treated with 0.5 mg entecavir/day with a
median follow-up of 11 months (3–23). While 79% of 104 NA
naïve patients achieved virologic response, control of HBV repli-
cation was obtained in only 54% of 57 NA experienced patients
treated either with lamivudine or adefovir and switched to ente-
cavir monotherapy. As expected and based on previous experi-
ence, patients with lamivudine resistant mutations at the start
of entecavir therapy were prone to develop resistance to enteca-
vir and had a reduced probability of achieving viral control as
compared to lamivudine naïve patients. Yet, efﬁcacy of entecavir
in lamivudine experienced patients who did not develop these
mutations remained unchanged. Baseline HBeAg negativity, high
ALT, low serum HBV-DNA and absence of lamivudine resistant
mutations were predictors of viral response to entecavir. In con-
trast, prior treatment with adefovir had no negative impact on
anti-viral response after switching to entecavir monotherapy,
irrespective of presence or absence of resistance to adefovir.
These results conﬁrm previous reports and add new information
on the reduced potency and risk of administering entecavir to
lamivudine experienced CHB patients with YMDD mutants. Yet
it is important to note that the potency of entecavir monotherapy
remained intact in adefovir experienced patients as well as in
patients treated previously with lamivudine who had no historyJournal of Hepatology 20
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E-mail address: shouval@cc.huji.ac.ilof lamivudine resistant mutations. This observation is reassuring
for many of the CHB patients in the community who originally
were treated with lamivudine without developing YMDD muta-
tions and who were switched by their physicians to entecavir.
Although this study has a number of limitations including: the
heterogeneous patient population, the absence of a control group
treated by the ‘‘add on” strategy recommended in the EASL Clin-
ical Practice Guidelines, as well as the short follow-up, it provides
useful information for the management of CHB.The impact of hepatic steatosis on the functional reserve of
the liver following portal vein occlusion
Pre-operative portal vein embolization (PVE) and portal vein liga-
tion (PVL) are well established means to increase the volume of
the future liver remnant (FLR) in candidates for extensive hepatic
resection. Despite the controversy concerning which of the two
procedures is superior, both techniques lead to atrophy of the
portal ﬂow-deprived liver lobe and to compensatory hypertrophy
of the contralateral FLR. Such hypertrophy is essential for the
preservation of hepatic functions and to avoid post-operative
hepatic decompensation. Such procedures are by now common
practice in patients with unilateral hepatic metastasis or liver
tumors. Success of these procedures is dependent on the func-
tional reserve of the FLR prior to PVL or PVE. The growing number
of patients with non-alcoholic fatty liver disease (NAFLD) is pos-
ing a major challenge for pre-operative assessment of hepatic
functional reserve. In this issue, Hsiao and co-workers have used
an animal model of fatty liver in methionine-choline deﬁcient
rats to study the impact of fatty inﬁltration of the liver on the
regenerative and functional capacity of PVL rats. The investiga-
tors employed an extensive battery of tests for the assessment
of the various parameters tested, including a bromodeoxyuridine
assay for the assessment of DNA synthesis, immunohistochemical
staining, assessment of liver regeneration through determination
of restituted liver mass, conventional liver function tests, mea-
surement of apoptosis as well as pro-inﬂammatory cytokines
TNFa, IL-1a, IL-1b, IL-6 and IL-10, indocyanine green retention
test, quantitative RT-PCR for adiponectin, adiponectin receptor
type 1and type 2, peroxime proliferator-activated receptor a,
and 99mTc-DICIDA scanning.
Without going into details of this in-depth analysis, the inves-
tigators were able to demonstrate that PVL leads to a decreased
regenerative and functional capacity of the steatotic liver as
compared to non-steatotic liver. Furthermore, PVL in rats with
hepatic steatosis failed to boost Kupfer cell numbers as well as10 vol. 52 j 467–468
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the pro-inﬂammatory Kupfer cell mediated cytokines. Finally PVL
steatotic rats had evidence of disrupted adiponectin signalling
involved in liver regeneration. These results provide functional
and molecular evidence that hepatic steatosis leads to reduced
regenerative and functional capacity in PVL rats. Although these468 Journal of Hepatology 201data were obtained in an animal model system, they should be
taken into account when calculating the volume of hepatic mass
to be resected in patients who are candidates for portal vein liga-
tion or embolization.0 vol. 52 j 467–468
